Company Information
About Vitura Health Limited (ASX: VIT)
Vitura Health Limited is a digital health company with a focus on various health-related businesses. It operates in three main segments. The Medical segment is involved in selling and distributing medical cannabis products. The Clinics segment runs medicinal cannabis clinics. The Consumer segment deals with non-medical consumer products in Australia and Asia.
The company runs CanView, an online platform managed by Burleigh Heads Cannabis, which provides over 350 therapeutic products to prescribers, patients, pharmacies, and suppliers in Australia. Besides CanView, Vitura Health owns Doctors on Demand Pty Ltd, a telehealth service offering primary health solutions, and Cannadoc Health Pty Ltd, where it has a 75.5% stake, which is a medicinal cannabis clinic that provides telehealth consultations.
Financially, Vitura Health reported a revenue of AUD 119.67 million and a net income of AUD 9.40 million. The company has seen significant growth with a 75.16% increase in revenue and a 128.31% improvement in net income year on year. Founded in 2018, Vitura Health now employs 121 people.
The website for Vitura Health is https://www.vitura.com.au/ and recent acquisitions include Doctors on Demand Pty Ltd, which was completed on October 19, 2023, for a transaction value that resulted in a 72% decrease, equating to AUD 15.73 million.
Top Australian Brokers
- eToro - Social and copy trading platform - Read our review
- IC Markets - Experienced and highly regulated - Read our review
- Pepperstone - Trading education - Read our review
Vitura Health Limited (ASX: VIT) Live Chart
Vitura Health Limited (ASX: VIT) Forecast
Financial analysts have a consensus 12-month price target for Cronos Australia Ltd. at AU$0.14. This target is unanimous among the analysts and suggests a potential increase of 41.41% from the company’s recent trading price of AU$0.10.
Latest ASX News
Vitura Health (ASX: VIT) Performance
Vitura Health (ASX: VIT) Fundamentals
Vitura Health (ASX: VIT) Competitors
Don’t Buy Just Yet
You will want to see this before you make any decisions.
Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.
Our experts picked out The 5 best ASX shares to buy in 2024.
We’re giving away this valuable research for FREE.
Click below to secure your copy